Filter
Exclude
Time range
-
Near
Oncology News Central @OncNewsCentral
4 Nov 2024
FDA approves #OptuneLua, the first #TTF device for metastatic #NSCLC. Results from the phase 3 LUNAR trial show improved survival with fewer side effects. bit.ly/3UaTfNG @LealTiciana @WinshipAtEmory #TumorTreatingFields #LungCancerAwareness

FDA Approves Tumor Treating Fields Device (Optune Lua) for Metastatic NSCLC

The FDA approved Optune Lua, a tumor treating fields device, for use in certain adults with metastatic NSCLC receiving PD-1/PD-L1 inhibitors or docetaxel.

oncologynewscentral.com
1
3
333
adam nowlan, md, mph @adamnowlan
31 Aug 2023
Proud to be 1 of 2 #optunelua certified prescribers in the state of Georgia #piedmontcancer #lungcancer
PDBrown
 @PDBrownOnc
30 Aug 2023
If results EF-14 (GBM) weren’t convincing re: efficacy of TumorTreatment Fields (TTF) LUNAR trial mets NSCLC docetaxel or immuno /-TTF ↑↑ OS w/ TTF thelancet.com/journals/lanon…
5
476
Load more